New drugs are not enough-drug repositioning in oncology: An update

被引:64
|
作者
Armando, Romina Gabriela [1 ]
Gomez, Diego Luis Mengual [1 ]
Gomez, Daniel Eduardo [1 ]
机构
[1] Natl Univ Quilmes, Sci & Technol Dept, Lab Mol Oncol, Roque Saenz Pena 352,B1876, Bernal, Argentina
关键词
drug; repositioning; repurposing; oncology; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HIV PROTEASE INHIBITORS; CANCER STEM-CELLS; PHOSPHODIESTERASE TYPE 5; HUMAN PROSTATE-CANCER; PHASE-II TRIAL; OVEREXPRESSING TISSUE INHIBITOR; MYELOID-LEUKEMIA MECHANISMS; CALCIUM-CHANNEL ANTAGONISTS; ENDOTHELIAL GROWTH-FACTOR;
D O I
10.3892/ijo.2020.4966
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Drug repositioning refers to the concept of discovering novel clinical benefits of drugs that are already known for use treating other diseases. The advantages of this are that several important drug characteristics are already established (including efficacy, pharmacokinetics, pharmacodynamics and toxicity), making the process of research for a putative drug quicker and less costly. Drug repositioning in oncology has received extensive focus. The present review summarizes the most prominent examples of drug repositioning for the treatment of cancer, taking into consideration their primary use, proposed anticancer mechanisms and current development status.
引用
收藏
页码:651 / 684
页数:34
相关论文
共 50 条
  • [21] Exploratory Analysis of Drug Lag in New Oncology Drugs Between Japan and the US
    Akio Maki
    Mamoru Narukawa
    Therapeutic Innovation & Regulatory Science, 2023, 57 : 671 - 677
  • [22] The Importance of Bioactivation in Computer-Guided Drug Repositioning. Why the Parent Drug is Not Always Enough
    Talevi, Alan
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2016, 16 (19) : 2078 - 2087
  • [23] Drug repositioning, a new alternative in infectious diseases
    Serafin, Marissa Bolson
    Horner, Rosmari
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2018, 22 (03): : 252 - 256
  • [24] Transcriptional data: a new gateway to drug repositioning?
    Iorio, Francesco
    Rittman, Timothy
    Ge, Hong
    Menden, Michael
    Saez-Rodriguez, Julio
    DRUG DISCOVERY TODAY, 2013, 18 (7-8) : 350 - 357
  • [25] Update on New Drugs in Dermatology
    Shokeen, Divya
    CUTIS, 2016, 98 (05): : E26 - E27
  • [26] Drug Prices and Value of Oncology Drugs in Italy
    Russo, Pierluigi
    Marcellusi, Andrea
    Zanuzzi, Matteo
    Carletto, Angelica
    Fratto, Maria Elisabetta
    Favato, Giampiero
    Staniscia, Tommaso
    Romano, Ferdinando
    VALUE IN HEALTH, 2021, 24 (09) : 1273 - 1278
  • [27] DEVELOPMENT OF NEW DRUGS - UPDATE
    不详
    CLINICAL BULLETIN, 1979, 9 (04) : 169 - 170
  • [28] The notorious "drug lag" for oncology drugs in Japan
    Yonemori, Kan
    Hirakawa, Akihiro
    Ando, Masashi
    Hirata, Taizo
    Yunokawa, Mayu
    Shimizu, Chikako
    Katsumata, Noriyuki
    Tamura, Kenji
    Fujiwara, Yasuhiro
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (04) : 706 - 712
  • [29] The notorious “drug lag” for oncology drugs in Japan
    Kan Yonemori
    Akihiro Hirakawa
    Masashi Ando
    Taizo Hirata
    Mayu Yunokawa
    Chikako Shimizu
    Noriyuki Katsumata
    Kenji Tamura
    Yasuhiro Fujiwara
    Investigational New Drugs, 2011, 29 : 706 - 712
  • [30] DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information
    Amelio, I.
    Gostev, M.
    Knight, R. A.
    Willis, A. E.
    Melino, G.
    Antonov, A. V.
    CELL DEATH & DISEASE, 2014, 5 : e1051 - e1051